ReviewArchives of microbiology2026
CRISPR/Cas systems in fungal biotechnology: advancing high-value metabolite synthesis for industrial and food security applications.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungi serve as pivotal industrial platforms to produce essential compounds from pharmaceuticals like antibiotics and statins to diverse enzymes, organic acids and nutraceuticals. Fungi drive innovation across the medical, food and biofuel sectors through the synthesis of specialized pigments, flavors and bioactive molecules. Despite this potential, the development of efficient genetic toolkits has historically been slowed by low homologous recombination rates and biological complexity of diverse fungal taxa. The adaptation of CRISPR/Cas technologies including Cas9, Cas12a (Cpf1), and base editing has recently bypassed these bottlenecks and offers record precision in fungal genome engineering. This review provides a detailed analysis of current mechanistic approaches such as the use of ribonucleoprotein (RNP) complexes and specialized promoters for guide RNA expression. We have explored how these tools enable the multiplexed editing of genes and the fine-tuning of transcriptional modulation (i.e. CRISPR inactivation/activation) to redirect target metabolites for high industrial output by optimizing fungal physiology. Furthermore, the integration of CRISPR-based biosensors for the rapid, high-sensitivity detection of fungal pathogens, highlighting the dual role of these technologies in both production and food security has also been discussed.
Indexed as
Identifiers
41724842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.